Shared on 21 Oct 25
Fair value Increased 1.12%Analyst Commentary Highlights Margin Optimism as ResMed Faces Market Headwinds and Patent Challenge
Analysts have raised their price target for ResMed to $295 from $292, citing improved profit margin expectations and better anticipated gross margin expansion. This comes despite concerns over slower market growth dynamics.
Shared on 04 Aug 25
Fair value Increased 8.53%Digital Health Platforms Will Expand Sleep Apnea Treatment Globally
The upward revision in ResMed’s consensus price target reflects a modest increase in its future P/E multiple amid stable profit margins, resulting in a new fair value estimate of $289.71. What's in the News Repurchased 419,000 shares for $100 million, completing 9,210,000 shares repurchased ($863.38 million) under the long-term buyback program.
Shared on 07 May 25
Fair value Increased 2.75%Calabasas Facility And NightOwl Test Will Elevate Production Efficiency
Shared on 30 Apr 25
Fair value Decreased 3.39%Calabasas Facility And NightOwl Test Will Elevate Production Efficiency
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 23 Apr 25
Fair value Increased 0.21%Calabasas Facility And NightOwl Test Will Elevate Production Efficiency
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 16 Apr 25
Fair value Decreased 1.21%Calabasas Facility And NightOwl Test Will Elevate Production Efficiency
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 0.25%Calabasas Facility And NightOwl Test Will Elevate Production Efficiency
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 2.09%Calabasas Facility And NightOwl Test Will Elevate Production Efficiency
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Increased 0.26%Calabasas Facility And NightOwl Test Will Elevate Production Efficiency
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Calabasas Facility And NightOwl Test Will Elevate Production Efficiency
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 10 Mar 25
Fair value Decreased 0.55%Calabasas Facility And NightOwl Test Will Elevate Production Efficiency
AnalystConsensusTarget made no meaningful changes to valuation assumptions.